CVS HEALTH CORPORATION (CVS)
Consumer Cyclical › Retail-Drug Stores and Proprietary Stores
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 1.28 — trading near book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -1.4%
- Revenue growing at 8% annually
CVS HEALTH CORPORATION (CVS) is a Consumer Cyclical company operating in Retail-Drug Stores and Proprietary Stores, listed on the NYSE , with a market capitalisation of $96.5 billion . Key value metrics: P/B ratio 1.28, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CVS HEALTH CORPORATION — Fundamental Analysis Summary
On financial health, CVS shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -1.4% (sector average: 1.7%), and manageable leverage with a debt-to-equity ratio of 0.86.
StockPik's composite Value Score for CVS is 63/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CVS reports a solid gross margin of 45.1% (sector average: -36.6%) and a modest operating margin of 0.9%.
CVS shows revenue growing at 8% year-over-year, with earnings declining at 62%.
CVS pays a solid dividend yield of 3.5%.